Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting
Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting . (MENAFN - GlobeNewsWire - Nasdaq) All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967026/Beam-Therapeutics-Announces-New-Data-From-BEACON-Phase-12-Clinical-Trial-Of-BEAM-101-In-Sickle-Cell-Disease-At-American-Society-Of-Hematology-ASH-Annual-Meeting
2024-12-07
rss
(MENAFN - GlobeNewsWire - Nasdaq) All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia ...
Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 In Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting